Pharmaceutical wastewater
A connected industry library.
Trace production, cleaning and concentrated side-streams separately. Connect each to its pollutants, treatment conditions and original technical references.
Country coverage & industry connections
Country links count catalog associations, not verified plants or proof that every sub-industry operates there. The right-hand branches are industry references.
Browse all country libraries
Production. Water. Treatment.
Choose a branch, then select a connection. Read what supports it, when it applies and where it stops.
Mother liquors and wash waters need separate characterisation.
All documented connections
| Production stream | Water challenge | Treatment / control | When it applies |
|---|---|---|---|
| Chemical API synthesis · Synthesis mother liquor | Solvents & concentrated organics | Segregate for recovery | Assess solvent recovery before combining with dilute effluent. Identify composition, compatibility and safe residual handling. Recovery does not establish removal of the active ingredient. IFC / World Bank Group US Environmental Protection Agency |
| Chemical API synthesis · Pretreated synthesis water | Residual API & refractory compounds | Test targeted polishing | Assess adsorption or oxidation against the identified compounds. Verify the actual target and treatment by-products. Low bulk COD does not prove absence of active compounds. IFC / World Bank Group World Health Organization |
| Fermentation & biotechnology · Spent fermentation broth | Biodegradable load & nitrogen | Assess biological treatment | Test the pretreated stream for organic and nitrogen treatment. Check inhibition, batch variation and residual antibiotics. Biodegradable broth is not proof of antibiotic removal. US Environmental Protection Agency World Health Organization |
| Fermentation & biotechnology · Biological culture effluent | Biological containment duty | Validate inactivation if needed | Assess containment and inactivation before ordinary treatment. Base the procedure on the actual organism and biohazard. An ordinary filter is not validated biological inactivation. IFC / World Bank Group |
| Mixing & formulation · Mixing & product transfer | Product & excipient losses | Prevent & segregate losses | Examine product recovery and first-rinse collection at source. Keep recovery compatible with product-quality requirements. A formulation category does not define one fixed wastewater quality. US Environmental Protection Agency US Environmental Protection Agency |
| Mixing & formulation · Antibiotic product rinsing | Antibiotic pollution risk | Assess compound-specific controls | Include antibiotic pollution in the manufacturing risk assessment. Identify the antibiotic and a defensible monitoring target. Conventional indicators alone do not establish antibiotic safety. World Health Organization |
| Equipment cleaning · Acid / alkali cleaning | pH & cleaning-chemical peaks | Separate, balance & adjust pH | Meter suitable reagents after characterising the cleaning cycle. Confirm compatibility before any mixing. A neutral pH does not establish API or disinfectant removal. IFC / World Bank Group IFC / World Bank Group |
| Equipment cleaning · Campaign changeover wash | Intermittent concentrated losses | Reduce & collect at source | Assess cleaning losses and keep concentrated fractions identifiable. Retain validated cleaning and product-quality requirements. Waste reduction must not compromise manufacturing hygiene. US Environmental Protection Agency US Environmental Protection Agency |
| Concentrates & residuals · Saline process liquor | Dissolved salts & residual compounds | Assess separate concentrate route | Evaluate salt separation alongside concentrate management. Check scaling, organics and safe residual disposal. An MBR is not a desalination or universal API barrier. IFC / World Bank Group IFC / World Bank Group |
| Concentrates & residuals · Treatment sludge | Water & retained pollutants | Characterise & dewater | Dewater residuals within a characterised waste-management route. Confirm cake classification and return-filtrate treatment. Dewatering does not destroy retained pharmaceutical compounds. IFC / World Bank Group IFC / World Bank Group |
Equipment in context
Equipment follows the treatment duty. Flow, solids, fats, biodegradability and the receiving route still require a site assessment.
Original references
Industry reference, not local sampling, a national discharge limit or validated API removal. Determine the product, compounds, biological hazards, discharge route and permit before selecting a treatment train.
EHS Guidelines for Pharmaceuticals and Biotechnology Manufacturing
GIIP reference for API and secondary pharmaceutical manufacturing. Additional controls depend on the actual active compounds, toxicity and site conditions.
especially those associated with active ingredientsRead original source ↗Development Document for Final Effluent Limitations Guidelines and Standards for the Pharmaceutical Manufacturing Point Source Category
Historical US technical development document used for process distinctions and treatment principles, not current permit limits for other jurisdictions or a universal performance claim.
specific processing steps on individual process lines may differRead original source ↗Pharmaceutical Manufacturing Effluent Guidelines
US regulatory category reference showing fermentation, extraction, synthesis, formulation and research as distinct operations. No US limits are assigned to another country.
Mixing/Compounding and FormulationRead original source ↗Guidance on wastewater and solid waste management for manufacturing of antibiotics
WHO guidance overview on antibiotic manufacturing pollution, antimicrobial resistance and risk management. No numeric antibiotic targets are copied here; compound-specific evaluation is required.
Pollution contributes to antibiotic resistanceRead original source ↗Guides to Pollution Prevention: The Pharmaceutical Industry
Historical advisory source-reduction reference. It supports examining recovery and cleaning losses, not selecting a modern discharge limit or certifying a process.
source reduction and recyclingRead original source ↗General EHS Guidelines — Wastewater and Ambient Water Quality
Cross-industry technical reference for stream separation, treatment and monitoring. Confirm current national requirements and the actual receiving route separately.
quality, quantity, frequency and sourcesRead original source ↗Questions before selecting a treatment
Why separate API synthesis from formulation?
Their operations and waste streams differ. Use the actual process, product and cleaning cycle to define the sampling plan.
Does meeting COD prove antibiotic removal?
No. Assess the relevant antibiotic separately and establish a suitable monitoring target; bulk organic indicators alone cannot demonstrate it.
Can MBR alone treat every pharmaceutical effluent?
No universal assignment is made here. Test toxicity and biodegradability, then consider salts, active compounds and residuals as separate duties.
Do these references supply my local discharge limits?
No. Confirm the country, receiving sewer or water body, current permit and compound-specific requirements before selecting compliance targets.
What information should a pharmaceutical enquiry include?
Provide the production route, flow profile, separate cleaning streams, known compounds and analyses. Include toxicity, salinity, biological hazards and the proposed outlet where relevant.
Bring your process into the picture.
Share your country, production stream and available water analysis to assess a suitable treatment train.
Pharmaceutical Manufacturing — water evidence database
Public guides, reported developments and reviewed evidence. Counts describe this library’s coverage.
Country & measurePharmaceutical Manufacturing
- Related guides
- 194
- Reported events
- 0
- Reviewed facts
- 12
- Published dossiers
- 1
- Independent sources
- 1
Guides are article candidates, events are source-supported reports, and facts are reviewed records. Countries and industries overlap; grouped counts cannot be added into a global total.
Country × industry coverage
Select a cell to inspect its records. Coverage measures published material, never market size, factories or local project volume.
A dash means coverage is unknown or unconnected. A verified zero is shown only when the metric scope is known.
Daily public additions
First verified public appearance in this library, by UTC+8 day. Source publication dates do not create historical growth.
History is accumulating. Missing or failed days remain gaps; a single snapshot cannot establish a trend. Historical baseline and backfill are labelled separately.
Inspect recorded days and changes
| Day (UTC+8) | Coverage status | new records | Historical backfill | Revised | Withdrawn | Restored |
|---|---|---|---|---|---|---|
| 2026-10-15 | Partial: confirmed material only | — | 0 | 0 | 0 | 0 |
| 2026-10-16 | Partial: confirmed material only | 1 | 0 | 0 | 0 | 0 |
| 2026-10-17 | Partial: confirmed material only | 2 | 0 | 0 | 0 | 0 |
| 2026-10-18 | Partial: confirmed material only | 1 | 0 | 0 | 0 | 0 |
| 2026-10-19 | Partial: confirmed material only | — | 0 | 0 | 0 | 0 |
| 2026-10-20 | Partial: confirmed material only | — | 0 | 0 | 0 | 0 |
| 2026-10-21 | Partial: confirmed material only | 1 | 0 | 0 | 0 | 0 |
| 2026-10-22 | Partial: confirmed material only | 1 | 0 | 0 | 0 | 0 |
| 2026-10-23 | Partial: confirmed material only | 1 | 0 | 0 | 0 | 0 |
| 2026-10-24 | Partial: confirmed material only | — | 0 | 0 | 0 | 0 |
| 2026-10-25 | Partial: confirmed material only | 1 | 0 | 0 | 0 | 0 |
| 2026-10-26 | Partial: confirmed material only | — | 0 | 1 | 0 | 0 |
| 2026-10-27 | Partial: confirmed material only | — | 0 | 0 | 0 | 0 |
| 2026-10-28 | Partial: confirmed material only | 3 | 0 | 0 | 0 | 0 |
| 2026-10-29 | Partial: confirmed material only | 2 | 0 | 0 | 0 | 0 |
| 2026-10-30 | Partial: confirmed material only | 1 | 0 | 0 | 0 | 0 |
| 2026-10-31 | Partial: confirmed material only | 1 | 0 | 0 | 0 | 0 |
| 2026-11-01 | Partial: confirmed material only | — | 0 | 0 | 0 | 0 |
| 2026-11-02 | Partial: confirmed material only | — | 0 | 0 | 0 | 0 |
| 2026-11-03 | Partial: confirmed material only | 1 | 0 | 0 | 0 | 0 |
| 2026-11-04 | Partial: confirmed material only | — | 0 | 0 | 0 | 0 |
| 2026-11-05 | Partial: confirmed material only | 2 | 0 | 0 | 0 | 0 |
| 2026-11-06 | Partial: confirmed material only | 2 | 0 | 0 | 0 | 0 |
| 2026-11-07 | Partial: confirmed material only | — | 0 | 0 | 0 | 0 |
| 2026-11-08 | Partial: confirmed material only | 1 | 0 | 0 | 0 | 0 |
| 2026-11-09 | Partial: confirmed material only | 3 | 0 | 0 | 0 | 0 |
| 2026-11-10 | Partial: confirmed material only | — | 0 | 0 | 0 | 0 |
| 2026-11-11 | Partial: confirmed material only | — | 0 | 0 | 0 | 0 |
| 2026-11-12 | Partial: confirmed material only | 1 | 0 | 0 | 0 | 0 |
| 2026-11-13 | Partial: confirmed material only | — | 0 | 0 | 0 | 0 |
| 2026-11-14 | Partial: confirmed material only | — | 0 | 0 | 0 | 0 |
| 2026-11-15 | Partial: confirmed material only | 1 | 0 | 0 | 0 | 0 |
| 2026-11-16 | Partial: confirmed material only | — | 0 | 0 | 0 | 0 |
| 2026-11-17 | Partial: confirmed material only | 1 | 0 | 0 | 0 | 0 |
| 2026-11-18 | Partial: confirmed material only | 15 | 0 | 0 | 0 | 0 |
| 2026-11-19 | Partial: confirmed material only | 1 | 0 | 0 | 0 | 0 |
| 2026-11-20 | Partial: confirmed material only | 2 | 0 | 0 | 0 | 0 |
| 2026-11-21 | Partial: confirmed material only | 1 | 0 | 0 | 0 | 0 |
| 2026-11-22 | Partial: confirmed material only | 1 | 0 | 0 | 0 | 0 |
| 2026-11-23 | Partial: confirmed material only | — | 0 | 0 | 0 | 0 |
Current sources and reviewed facts
Two separate stocks at the published watermark. No historical stock line is reconstructed from article dates.
Record explorer
Inspect the records behind the selected coverage or day. Source links open the original publisher.
| Record type | Record | Country | First public verification | Evidence |
|---|---|---|---|---|
| Guide candidate | MBR vs Activated Sludge for Greenville Pharmaceutical WastewaterEnglish source title | United States | 2026-11-22 15:19 | Open the record for its evidence |
| Guide candidate | Pharmaceutical Wastewater Treatment in France: MBR Selection GuideEnglish source title | France | 2026-11-21 15:32 | Open the record for its evidence |
| Guide candidate | Pharmaceutical Wastewater Treatment in Costa Rica: 2026 GuideEnglish source title | Costa Rica | 2026-11-20 15:24 | Open the record for its evidence |
| Guide candidate | MBR vs Activated Sludge for Chattanooga Pharmaceutical WastewaterEnglish source title | United States | 2026-11-20 15:24 | Open the record for its evidence |
| Guide candidate | Belt Filter Presses for Pharmaceutical Wastewater: Selection GuideEnglish source title | Country scope not reported | 2026-11-19 15:35 | Open the record for its evidence |
| Guide candidate | Pharmaceutical Wastewater Treatment in the Dominican RepublicEnglish source title | Dominican Republic | 2026-11-18 16:36 | Open the record for its evidence |
| Guide candidate | Pharmaceutical Wastewater Treatment in Germany: 2026 GuideEnglish source title | Germany | 2026-11-18 16:36 | Open the record for its evidence |
| Guide candidate | DAF vs. Clarifier for Pharma Wastewater in Cincinnati: 2026English source title | United States | 2026-11-17 14:46 | Open the record for its evidence |
| Guide candidate | Pharmaceutical Wastewater Treatment in Panama: 2026 GuideEnglish source title | Panama | 2026-11-15 14:40 | Open the record for its evidence |
| Guide candidate | PAC Dosing Systems for Pharmaceutical Wastewater: 2026 GuideEnglish source title | Country scope not reported | 2026-11-12 14:40 | Open the record for its evidence |
| Guide candidate | What ETP Does Novartis Need After Expanding Its Pharma Plant? 2026English source title | Country scope not reported | 2026-11-09 14:38 | Open the record for its evidence |
| Guide candidate | How Do Pharma Plants Near Alachua Meet Sewer Limits?English source title | United States | 2026-11-09 14:38 | Open the record for its evidence |
Related guides
Technical and news articles provide reading paths and candidate associations; they do not prove a local project or reviewed fact.
- MBR vs Activated Sludge for Greenville Pharmaceutical WastewaterEnglish source title
- Pharmaceutical Wastewater Treatment in France: MBR Selection GuideEnglish source title
- Pharmaceutical Wastewater Treatment in Costa Rica: 2026 GuideEnglish source title
- MBR vs Activated Sludge for Chattanooga Pharmaceutical WastewaterEnglish source title
- Belt Filter Presses for Pharmaceutical Wastewater: Selection GuideEnglish source title
- Pharmaceutical Wastewater Treatment in the Dominican RepublicEnglish source title
- Pharmaceutical Wastewater Treatment in Germany: 2026 GuideEnglish source title
- DAF vs. Clarifier for Pharma Wastewater in Cincinnati: 2026English source title
- Pharmaceutical Wastewater Treatment in Panama: 2026 GuideEnglish source title
- PAC Dosing Systems for Pharmaceutical Wastewater: 2026 GuideEnglish source title
- What ETP Does Novartis Need After Expanding Its Pharma Plant? 2026English source title
- How Do Pharma Plants Near Alachua Meet Sewer Limits?English source title
- What ETP Does AstraZeneca Need After Expanding Its Pharma Plant? 2026English source title
- Pharmaceutical Wastewater Treatment in Colombia: 2026 Technology Selection & Compliance GuideEnglish source title
- MBR vs Conventional Activated Sludge for Pharma Wastewater 2026English source title
- Pharmaceutical Plant Pretreatment Near Norwich: 2026 GuideEnglish source title
- Flocculant Dosing Unit for Pharmaceutical Wastewater: 2026 GuideEnglish source title
- Pharmaceutical Wastewater Treatment in the Philippines: 2026 GuideEnglish source title
- Pharmaceutical Wastewater Treatment in Mexico: 2026 GuideEnglish source title
- Pharmaceutical Wastewater Treatment in Cameroon: 2026 GuideEnglish source title
- DAF vs. Clarifier for Pharmaceutical Wastewater in Farmville, 2026English source title
- Coagulant Dosing System for Pharmaceutical Wastewater: 2026 GuideEnglish source title
- Pharmaceutical Wastewater Treatment in Iraq: 2026 GuideEnglish source title
- Pharmaceutical Wastewater Treatment in Ivory Coast: 2026 GuideEnglish source title
More country-specific reading is available through the country links in the coverage table.
Recent reported developments
Source publication and first public verification are separate dates. Reported developments remain observations.
No source-supported events are public for this selection.
Comparable water samples
Compare only matching parameter, unit, water stage and scope. Individual facility samples never represent a national average or a continuous water-quality trend.
No group of at least two comparable, reviewed samples is available. Read individual evidence in the published dossiers.
Move from evidence to a treatment discussion
Carry the selected country and industry into your enquiry. Confirm influent conditions, discharge destination and operating scope with the engineering team.
Snapshot scope and provenance
- Version
- 86bf514f9965e134c11a5da6fa74714e460d9fa664973e377ff05f8dd3b34bad
- Industry classification version
- 2026-10-15.1
- Reviewed foundation version
- 20261015T105811-e19facf957c3
- Observation version
- ec4063e1203c11f4cde1b0b0cd605ff1e4a88de125a6bddfeabba96dafe156a0
- Public coverage watermark
- b13e9e980ea1373beb87c0d4c5b5337690ad0b30d73553a4a0e8129d8ec1d961
- Historical baseline cutoff
- Not reported
Only caller-frozen public records are counted. Language versions and revisions share a record identity; source versions share the independent source identity.

